See more : Whitehorse Gold Corp. (WHGDF) Income Statement Analysis – Financial Results
Complete financial analysis of Invivyd, Inc. (IVVD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Invivyd, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Torrent Pharmaceuticals Limited (TORNTPHARM.NS) Income Statement Analysis – Financial Results
- San Miguel Corporation (SMGBF) Income Statement Analysis – Financial Results
- Centrale del Latte d’Italia S.p.A. (CLI.MI) Income Statement Analysis – Financial Results
- Tang Palace (China) Holdings Limited (TNGPF) Income Statement Analysis – Financial Results
- Ishan Dyes & Chemicals Limited (ISHANCH.BO) Income Statement Analysis – Financial Results
Invivyd, Inc. (IVVD)
About Invivyd, Inc.
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.03M | 462.00K | 1.00K | 0.00 |
| Gross Profit | -2.03M | -462.00K | -1.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 158.66M | 179.21M | 182.89M | 62.12M |
| General & Administrative | 0.00 | 47.04M | 36.52M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.10M | 47.04M | 36.52M | 3.21M |
| Other Expenses | 0.00 | 6.71M | 118.00K | 0.00 |
| Operating Expenses | 205.76M | 226.26M | 219.41M | 65.33M |
| Cost & Expenses | 207.78M | 226.26M | 219.41M | 65.33M |
| Interest Income | 0.00 | 6.71M | 118.00K | 8.00K |
| Interest Expense | 0.00 | 43.08M | 0.00 | 0.00 |
| Depreciation & Amortization | 2.03M | 462.00K | 1.00K | 43.20M |
| EBITDA | -196.62M | -248.03M | -226.79M | -65.33M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -207.78M | -248.03M | -226.91M | -65.33M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.14M | 6.71M | -7.38M | 8.00K |
| Income Before Tax | -198.64M | -241.32M | -226.79M | -65.32M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -6.71M | 7.50M | -43.20K |
| Net Income | -198.64M | -234.60M | -234.29M | -65.32M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.81 | -2.17 | -2.11 | -0.59 |
| EPS Diluted | -1.81 | -2.17 | -2.11 | -0.59 |
| Weighted Avg Shares Out | 109.53M | 108.27M | 110.78M | 111.25M |
| Weighted Avg Shares Out (Dil) | 109.53M | 108.27M | 110.78M | 111.25M |
Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:18 AM ET Invivyd, Inc. (NASDAQ:IVVD ) Q3 2024 Earnings Conference Call November 14, 2024, 08:30 AM ET Company Participants Marc Elia - Chairperson, Board of Directors and Executive Committee Tim Lee - COO...
Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.36 per share a year ago.
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
WALTHAM, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced financial results for the quarter ended September 30, 2024, and recent business highlights.
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
WALTHAM, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announces that The New England Journal of Medicine (NEJM) has published a peer-reviewed Letter to...
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively
WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that a manuscript preprint conveying data from the CANOPY Phase 3 clinical trial of...
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
WALTHAM, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that management will participate in a fireside chat and 1x1 investor meetings at the...
Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024
WALTHAM, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, November 14, 2024, at 8:30...
Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability
WALTHAM, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today reported preliminary third quarter (Q3) 2024 financial results and an update to prior financial guidance.
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants
WALTHAM, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced positive 12-month exploratory clinical efficacy data from the company's ongoing CANOPY Phase 3 clinical...
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced the upcoming presentations of pemivibart data from its Phase 1 and Phase 3 clinical...
Source: https://incomestatements.info
Category: Stock Reports